Tolebrutinib nears the MS approval finish line
After some stumbles out of the starting gate, an experimental treatment that’s in a group hoping to be the next big thing for people with multiple sclerosis (MS) is a step closer to U.S. Food and Drug Administration (FDA) approval. Tolebrutinib, developed by Sanofi, has been designated as a Breakthrough Therapy for the treatment of adults with non-relapsing secondary progressive MS (nrSPMS). The designation is intended to speed the development…Continue Reading